United Therapeutics (NASDAQ:UTHR)‘s stock had its “underperform” rating reiterated by equities researchers at Credit Suisse Group in a research note issued on Thursday. They presently have a $118.00 price objective on the biotechnology company’s stock. Credit Suisse Group’s price target indicates a potential downside of 15.42% from the stock’s previous close.
A number of other research analysts have also recently issued reports on UTHR. ValuEngine raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 26th. BidaskClub raised United Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Zacks Investment Research raised United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Wedbush reaffirmed an “outperform” rating and issued a $232.00 price target (up from $213.00) on shares of United Therapeutics in a report on Wednesday, December 27th. Finally, Cowen reaffirmed a “hold” rating and issued a $129.00 price target on shares of United Therapeutics in a report on Friday, October 27th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $140.27.
Shares of United Therapeutics (NASDAQ:UTHR) traded down $0.02 during midday trading on Thursday, hitting $139.51. The company’s stock had a trading volume of 425,793 shares, compared to its average volume of 360,801. The company has a market capitalization of $6,028.37, a PE ratio of 12.30 and a beta of 1.41. United Therapeutics has a 12 month low of $112.01 and a 12 month high of $169.89.
In related news, CEO Martine A. Rothblatt sold 1,241 shares of United Therapeutics stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $128.95, for a total value of $160,026.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher Causey sold 580 shares of United Therapeutics stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $122.00, for a total value of $70,760.00. Following the completion of the sale, the director now owns 2,135 shares of the company’s stock, valued at $260,470. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,508 shares of company stock valued at $1,774,621. Corporate insiders own 7.80% of the company’s stock.
Several institutional investors have recently bought and sold shares of UTHR. Quantbot Technologies LP grew its position in shares of United Therapeutics by 537.3% during the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock worth $114,000 after buying an additional 822 shares during the period. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of United Therapeutics during the 3rd quarter worth about $156,000. Toronto Dominion Bank grew its position in shares of United Therapeutics by 244.7% during the 3rd quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock worth $223,000 after buying an additional 1,351 shares during the period. Meiji Yasuda Asset Management Co Ltd. acquired a new position in shares of United Therapeutics during the 3rd quarter worth about $233,000. Finally, TLP Group LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth about $246,000.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.